Kjaer Thomas Nordstrøm, Ornstrup Marie Juul, Poulsen Morten Møller, Jørgensen Jens Otto Lunde, Hougaard David Michael, Cohen Arieh Sierra, Neghabat Shadman, Richelsen Bjørn, Pedersen Steen Bønløkke
Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Aarhus C, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark.
Prostate. 2015 Sep;75(12):1255-63. doi: 10.1002/pros.23006. Epub 2015 May 4.
Resveratrol is a naturally occurring polyphenol with purported inhibitory effects on prostate growth and cancer development. A number of studies have demonstrated that resveratrol reduces prostate growth in animal models and reduces prostate cell growth in vitro. Based on these pre-clinical findings, interest in resveratrol is increasing in relation to the management of benign prostate hyperplasia (BPH) and prostate cancer. So far, no human trials have evaluated the effects of resveratrol on circulating androgens, prostate size, or biochemical markers of prostate size.
In a randomized placebo controlled clinical study using two doses of resveratrol (150 mg or 1,000 mg resveratrol daily) for 4 months, we evaluated the effects on prostate size, prostate specific antigen (PSA) and sex steroid hormones in 66 middle-aged men suffering from the metabolic syndrome(MetS).
At baseline, prostate size and PSA were positively correlated (R = 0.34, P < 0.007) as was prostate size and age (R = 0.37, P < 0.003). Prostate size did not correlate with testosterone, free testosterone, dihydrotestosterone (DHT), or any other androgen precursor at baseline. The highest dose of resveratrol lowered the serum level of androstenedione 24% (P = 0.052), dehydroepiandrosterone (DHEA) 41% (P < 0.01), and dehydroepiandrosterone-sulphate (DHEAS) 50% (p<0.001), compared to the control group. However, prostate size and levels of PSA, testosterone, free testosterone and DHT remained unchanged.
In this population of middle-aged men suffering from MetS, high dose resveratrol (1,000 mg daily) administration for 4 months significantly lowered serum levels of the androgen precursors androstenedione, DHEA and DHEAS, whereas prostate size and circulating levels of PSA, testosterone, free testosterone, and dihydrotestosterone were unaffected. The present study suggests that resveratrol does not affect prostate volume in healthy middle-aged men as measured by PSA levels and CT acquired prostate volumes. Consequently, we find no support for the use of resveratrol in the treatment of benign prostate hyperplasia.
白藜芦醇是一种天然存在的多酚，据称对前列腺生长和癌症发展具有抑制作用。多项研究表明，白藜芦醇可减少动物模型中的前列腺生长，并在体外减少前列腺细胞生长。基于这些临床前研究结果，白藜芦醇在良性前列腺增生（BPH）和前列腺癌管理方面的关注度日益增加。到目前为止，尚无人体试验评估白藜芦醇对循环雄激素、前列腺大小或前列腺大小生化标志物的影响。
在一项随机安慰剂对照临床研究中，我们使用两种剂量的白藜芦醇（每日150毫克或1000毫克白藜芦醇），为期4个月，评估了其对66名患有代谢综合征（MetS）的中年男性前列腺大小、前列腺特异性抗原（PSA）和性类固醇激素的影响。
在基线时，前列腺大小与PSA呈正相关（R = 0.34，P < 0.007），前列腺大小与年龄也呈正相关（R = 0.37，P < 0.003）。在基线时，前列腺大小与睾酮、游离睾酮、二氢睾酮（DHT）或任何其他雄激素前体均无相关性。与对照组相比，最高剂量的白藜芦醇使血清雄烯二酮水平降低24%（P = 0.052），脱氢表雄酮（DHEA）降低41%（P < 0.01），硫酸脱氢表雄酮（DHEAS）降低50%（P < 0.001）。然而，前列腺大小以及PSA、睾酮、游离睾酮和DHT水平保持不变。
在这群患有MetS的中年男性中，高剂量白藜芦醇（每日1000毫克）给药4个月可显著降低雄激素前体雄烯二酮、DHEA和DHEAS的血清水平，而前列腺大小以及PSA、睾酮、游离睾酮和二氢睾酮的循环水平未受影响。本研究表明，通过PSA水平和CT获取的前列腺体积测量，白藜芦醇对健康中年男性的前列腺体积没有影响。因此，我们不支持使用白藜芦醇治疗良性前列腺增生。
